Contribution of MiRNAs in the Pathogenesis of Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Nov 22

PMID 34804971

Citations 13

Authors

Soudeh Ghafouri-Fard

Ali Khanbabapour Sasi

Atefe Abak

Hamed Shoorei

Ali Khoshkar

Mohammad Taheri

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most frequently diagnosed cancer among females. Gene expression profiling methods have shown the deregulation of several genes in breast cancer samples and have confirmed the heterogeneous nature of breast cancer at the genomic level. microRNAs (miRNAs) are among the recently appreciated contributors in breast carcinogenic processes. These small-sized transcripts have been shown to partake in breast carcinogenesis through modulation of apoptosis, autophagy, and epithelial-mesenchymal transition. Moreover, they can confer resistance to chemotherapy. Based on the contribution of miRNAs in almost all fundamental aspects of breast carcinogenesis, therapeutic intervention with their expression might affect the course of this disorder. Moreover, the presence of miRNAs in the peripheral blood of patients potentiates these transcripts as tools for non-invasive diagnosis of breast cancer.

Citing Articles

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.

Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.

Nemours S, Sole C, Goicoechea I, Armesto M, Arestin M, Urruticoechea A Int J Mol Sci. 2025; 25(24.

PMID: 39769392 PMC: 11728027. DOI: 10.3390/ijms252413630.

Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.

Rahman M, Ghorai S, Panda K, Santiago M, Aggarwal S, Wang T Noncoding RNA Res. 2024; 11:22-37.

PMID: 39736851 PMC: 11683234. DOI: 10.1016/j.ncrna.2024.11.001.

Integrated miRNA Signatures: Advancing Breast Cancer Diagnosis and Prognosis.

Samara M, Thodou E, Patoulioti M, Poultsidi A, Thomopoulou G, Giakountis A Biomolecules. 2024; 14(11).

PMID: 39595529 PMC: 11591846. DOI: 10.3390/biom14111352.

A machine learning model revealed that exosome small RNAs may participate in the development of breast cancer through the chemokine signaling pathway.

Mo J, Li X, Lei L, Peng J, Liang X, Zhou H BMC Cancer. 2024; 24(1):1435.

PMID: 39574053 PMC: 11580650. DOI: 10.1186/s12885-024-13173-x.

References

Wong R . Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30:87. PMC: 3197541. DOI: 10.1186/1756-9966-30-87. View

Hu Z, Dong J, Wang L, Ma H, Liu J, Zhao Y . Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012; 33(4):828-34. DOI: 10.1093/carcin/bgs030. View

Qiu C, Huang F, Zhang Q, Chen W, Zhang H . miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients. J Clin Lab Anal. 2019; 33(8):e22966. PMC: 6805278. DOI: 10.1002/jcla.22966. View

Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P . Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer. Mol Cancer Res. 2018; 16(9):1348-1360. PMC: 6843115. DOI: 10.1158/1541-7786.MCR-17-0634. View

Singh R, Mo Y . Role of microRNAs in breast cancer. Cancer Biol Ther. 2013; 14(3):201-12. PMC: 3595302. DOI: 10.4161/cbt.23296. View

Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, Gonzalez-Alonso P . The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep. 2017; 7:41309. PMC: 5264595. DOI: 10.1038/srep41309. View

Pei Y, Lei Y, Liu X . MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. Biochim Biophys Acta. 2016; 1862(11):2177-2185. DOI: 10.1016/j.bbadis.2016.08.014. View

Han M, Hu J, Lu P, Cao H, Yu C, Li X . Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020; 11(1):43. PMC: 6976584. DOI: 10.1038/s41419-020-2250-5. View

Van Rooij E, Kauppinen S . Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6(7):851-64. PMC: 4119351. DOI: 10.15252/emmm.201100899. View

10.

Muluhngwi P, Krishna A, Vittitow S, Napier J, Richardson K, Ellis M . Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett. 2016; 388:230-238. PMC: 5318263. DOI: 10.1016/j.canlet.2016.12.007. View

11.

Long J, Ji Z, Jiang K, Wang Z, Meng G . miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1. Biomed Res Int. 2015; 2015:373574. PMC: 4615858. DOI: 10.1155/2015/373574. View

12.

Zhao J, Zou H, Han C, Ma J, Zhao J, Tang J . Circlular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/BARD1 axis. Cell Cycle. 2018; 17(24):2731-2744. PMC: 6343738. DOI: 10.1080/15384101.2018.1556058. View

13.

Chen P, He Y, Huang X, Tao S, Wang X, Yan H . modulates s-mediated autophagy in human luminal breast cancer cell lines. Oncotarget. 2017; 8(46):80709-80721. PMC: 5655233. DOI: 10.18632/oncotarget.21080. View

14.

Hamam R, Ali A, Alsaleh K, Kassem M, Alfayez M, Aldahmash A . microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016; 6:25997. PMC: 4867432. DOI: 10.1038/srep25997. View

15.

Zhang H, Sun D, Mao L, Zhang J, Jiang L, Li J . MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochem Biophys Res Commun. 2015; 465(4):702-13. DOI: 10.1016/j.bbrc.2015.08.053. View

16.

Zhou S, Huang Q, Zheng S, Lin K, You J, Zhang X . miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol. 2015; 37(5):6837-45. DOI: 10.1007/s13277-015-4500-1. View

17.

Liu G, Wang P, Zhang H . MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway. J Gene Med. 2019; 21(12):e3129. DOI: 10.1002/jgm.3129. View

18.

Jin J, Sun Z, Yang F, Tang L, Chen W, Guan X . miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. Arch Biochem Biophys. 2018; 645:54-60. DOI: 10.1016/j.abb.2018.03.015. View

19.

Meng C, Liu Y, Shen Y, Liu S, Wang Z, Ye Q . MicroRNA-26b suppresses autophagy in breast cancer cells by targeting DRAM1 mRNA, and is downregulated by irradiation. Oncol Lett. 2018; 15(2):1435-1440. PMC: 5774516. DOI: 10.3892/ol.2017.7452. View

20.

Liao X, Xiang Y, Yu C, Li J, Li H, Nie Q . STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 2017; 8(9):15763-15774. PMC: 5362521. DOI: 10.18632/oncotarget.15000. View